In­cyte’s IDO1 up­date on its Keytru­da com­bo scores some pos­i­tive re­views

In­cyte’s lat­est cut on the da­ta from a Phase I/II study of its com­bi­na­tion ther­a­py adding Mer­ck’s check­point star Keytru­da to its close­ly watched IDO1 en­zyme in­hibitor epaca­do­stat for melanoma is con­tin­u­ing to im­press ob­servers. And that is all bod­ing well for a new­ly launched Phase III study.

By all means, it’s still ear­ly days on out­comes, but in this new pack­age re­leased ahead of ES­MO there was an im­prove­ment in the ob­jec­tive re­sponse da­ta, which hit an ORR of 55% (or 12 out of 22 pa­tients) among all pa­tients, in­clud­ing 5 com­plete re­spons­es (23%) and 7 par­tial re­spons­es (32%). Among treat­ment-naive pa­tients the ORR was 58% and oth­er tu­mor types be­ing stud­ied demon­strat­ed ORRs rang­ing from 27% to 60%, notes RBC.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.